The FDA has designated Thetis Pharmaceuticals’ experimental treatment for pancreatic cancer an “orphan drug,” a label that makes the company eligible for tax credits and other financial incentives.
The designation comes as the company gears up for early-stage human testing of the drug, TP-317, at Yale Cancer Center next year.